PureTech Founded Entity Vedanta Biosciences Announces $106.5

Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023


Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q... | April 25, 2023

Related Keywords

United States , South Korea , Cambridge , Cambridgeshire , United Kingdom , Korea , American , Martin Heidecker , Atlantic Neptune , Curt Labelle , Bernat Olle , Christopher Viehbacher , Bharatt Chowrira , Neil Tiwari , Twitter , Department Of Health , Korea Investment Securities Us Inc , Biomedical Advanced Research , Development Authority , Journal Of The American Medical Association , Puretech Health , Biogen Inc , Pfizer Inc , Human Services , Nasdaq , Korea Investment Securities Asia Ltd , Action Fund , Melinda Gates Foundation , Administration For Strategic Preparedness , Founded Entity , Vedanta Biosciences , Skyviews Life Science , Reimagined Ventures , Fiscus Ventures , Korea Investment Partners , Korea Investment , Securities Asia , Revelation Partners , Seventure Partners , Hambro Perks , Biosciences Announces , Advance Pipeline , Defined Bacterial Consortia , Chief Executive Officer , American Medical Association , Strategic Preparedness , Managing Partner , Global Healthcare Strategies , Chief Investment Officer , Chief Business , Operating Officer , Charles Sherwood , Associate General Counsel , Vedanta Board , Bacterial Consortia , Founded Entities , Puretech Health Plc Stock Exchange , News , Information , Press Release , Financing , Hill , Nable , Pivotal , Hase , , Study , F , E303 , Or , Recurrent , Difficile , O , Begin , Y , Q , Also , Support , E202 , Ulcerative , N Prtc Gb00by2z0h74 ,